Last reviewed · How we verify
Liraglutide Pen Injector [Victoza]
Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels.
Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby reducing blood glucose levels. Used for Type 2 diabetes mellitus, Weight management in obese or overweight patients with weight-related comorbidities.
At a glance
| Generic name | Liraglutide Pen Injector [Victoza] |
|---|---|
| Sponsor | Imperial College London |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It binds to GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, inhibits glucagon release when blood glucose is elevated, and delays gastric emptying to reduce postprandial glucose spikes. These combined effects improve glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Weight management in obese or overweight patients with weight-related comorbidities
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Hypoglycemia